中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.015 seconds)

    Pharmaceutical combinations
    12.
    发明授权
    Pharmaceutical combinations 有权

    公开(公告)号：US10220038B2

    公开(公告)日：2019-03-05

    申请号：US15914479

    申请日：2018-03-07

    Applicant: Novartis AG

    Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

    IPC: A61K31/519 ,  A61K31/4188 ,  A61K31/505 ,  A61K31/496 ,  A61K31/506

    Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

    PHARMACEUTICAL COMBINATIONS
    13.
    发明申请
    PHARMACEUTICAL COMBINATIONS 审中-公开

    公开(公告)号：US20180015092A1

    公开(公告)日：2018-01-18

    申请号：US15683887

    申请日：2017-08-23

    Applicant: Novartis AG

    Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

    IPC: A61K31/519 ,  A61K31/506 ,  A61K31/496

    CPC classification number: A61K31/519 ,  A61K31/4188 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K2300/00

    Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

    COMBINATION THERAPY
    14.
    发明申请
    COMBINATION THERAPY 审中-公开
    组合治疗

    公开(公告)号：US20150290204A1

    公开(公告)日：2015-10-15

    申请号：US14440915

    申请日：2013-11-06

    Applicant: NOVARTIS AG

    Inventor： Qing Sheng ,  Hui-Qin Wang ,  Fang Li ,  Jinsheng Liang ,  Zhu Alexander Cao ,  John Monahan ,  Richard Versace

    IPC: A61K31/5377 ,  A61K31/506

    CPC classification number: A61K31/5355 ,  A61K31/365 ,  A61K31/395 ,  A61K31/416 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

    Abstract: A pharmaceutical combination comprising (a) a compound of formula (I), or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering from a proliferative disease; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

    Abstract translation: 一种药物组合，其包含（a）式（I）化合物或其药学上可接受的盐; 和（b）一种或多种至少一种靶向，降低或抑制Hsp90的内在ATP酶活性和/或通过泛素蛋白酶途径降解，靶向，降低或抑制Hsp90客体蛋白的化合物; 这种组合在治疗或预防增殖性疾病中的用途; 以及治疗患有增殖性疾病的受试者的方法; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。

Patent Agency Ranking